# - occuity

Occuity is set to revolutionise the way in which some of the world's most prevalent chronic diseases are detected and managed. Our devices work by safely shining a low power beam of light into the eye, collecting and analysing the return signal. They are unlike anything else currently on the market.

# Overview

Occuity have developed a novel, globally patented non-contacting technology that is able to accurately detect changes in the eye and thereby derive information not only about a patient's ocular health, but also about their broader wellbeing, particularly where this relates to chronic, life changing conditions. Occuity is developing its disruptive technology into a range of handheld devices aimed at some of the major healthcare challenges of our time such as Diabetes and Alzheimer's disease. Due to the size of the market, we are particularly interested in addressing diabetes by developing products that will enable earlier diagnosis of the

condition and deliver non-contacting, pain-free glucose monitoring.

## Overview

- Medtech Device Developer with disruptive non-contact handheld technology platform addressing markets worth tens of billions USD.
- First products aimed at Ophthalmology market due for release later this year. Clinical Trials scheduled for June 2022.

# **Commercial Traction**


- Multiple commercial partnerships in discussion with major players in the Optometry/Ophthalmology sector regarding orders worth circa £100m.
- Technology licensing agreement in discussion with global Optometry/ Ophtalmology OEM for use of patented technology in combined devices.

MORE >

- In discussion with mobile phone manufacturer regarding Glucose Monitor Technology
- The Team

50+ Years in Optics
100+ Years in MedTech
400+ Patents

Multiple Successful Raises and Exits



Technology covered by 15 international patents, more in draft.



- Contract terms agreed and ready to be signed with 10 distributors. Further in progress. First 500 product sales close to being committed.
- Grants of £1.5m won to progress several of the devices under development. Further grant applications are in process.







### ISSUER Occuity Ltd SECTOR Medical Instrumentation FOUNDED 6 Sept 2019 HEADQUARTERS Reading, UK

#### **KEY STATS**

Patents: 15+ Headcount: 35+ Market Opportunity: \$35bn

#### ROUND DETAILS

Target: c.£3m Pre-Money Value: £24m Share Price: £24

Shares: Ordinary (EIS) or Preference

#### **REGISTERED IN**

United Kingdom REGISTERED NO. 12192959

#### REGISTERED OFFICE

27 Old Gloucester St. London United Kingdom WC1N 3AX occuity

# Financials

- Projecting £610k revenue in 2022, £5.2M in 2023, £31.5M in 2024 rising to £435M in 2027.
- Strong Margins Gross margins c.75%, net profit margins c.45%.

Condensed P&L	2020	2021	2022	2023	2024	2025	2026	2027
(£'000)	Act	Act	Est	BM	BM	BM	BM	BM
Revenue	-	-	610	5,191	31,491	94,674	206,846	435,522
Total Cost of Sales	-	7	275	2,003	8,631	22,969	49,284	91,252
Gross Margin	-	(7)	334	3,188	22,860	71,705	157,561	344,270
%	0%	-	55%	61%	73%	76%	76%	79%
Total Operating Expenses	865	2,018	3,248	8,486	16,453	27,042	51,986	105,720
%	0%	-	533%	163%	52%	29%	25%	24%
Total Operating Profit	(865)	(2,025)	(2,913)	(5,298)	6,407	44,663	105,575	238,550
%	0%	-	-478%	-102%	20%	47%	51%	55%
Tax & Interest & Other I/E	209	156	515	1,069	(1,160)	(6,471)	(17,382)	(39,163)
Net Profit	(656)	(1,869)	(2,399)	(4,230)	5,247	38,192	88,193	199,387
%	0%	-	-	-	17%	40%	43%	46%

## **Current Raise**

- Raise at £24 per share. Pre-money valuation of c.£24m.
- Shares available as either Ordinary (EIS) or Preference Shares with 1 x distribution preference on exit value up to £48 per share, phasing out linearly to £72 per share after which no distribution preference will apply.
- EIS STATUS: Advanced assurance requested (previous rounds approved)

## **Contact Us & Further information**

A full Investment Memorandum is available. To express your interest and view this document, please visit our website or email us. Visit www.occuity.com/investors Email investment@occuity.com

FULL INVESTOR INFO >

**Disclaimer:** This document is being communicated to and is only available to persons who are "investment professionals", "self-certified sophisticated investors", "high net worth individuals" and any other person to whom it may otherwise lawfully be distributed in accordance with Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 as amended or Financial Services and Markets Act 2000 (Collective Investment Schemes) Order 2001 as amended. This communication should not be acted upon by any other person. This communication is an exempt communication under Section 21 of the Financial Services and Markets Act 2000 and has been prepared by Occuity Ltd. Occuity Ltd is not authorised and regulated by the Financial Conduct Authority. The information in this document is confidential and any reproduction, in whole or in part, is prohibited. This document does not constitute an offer to sell to, or a solicitation of an offer to subscribe from, anyone in any jurisdiction. Past performance is not a reliable indicator of future performance, nor are future forecasts or projections. Tax treatment depends on an individual's circumstances and may be subject to change in the future. Potential exits are contingent upon a successful fundraise and implementation of the business plan. This document contains only limited information provided in this document, or on interpretation of such information. Investing in start-ups and early stage businesses involves risks, including illiquidity (the inability to sell assets quickly or without substantial loss in value), lack of dividends, loss of investment and dilution, and should be done only as part of a diversified portfolio. Your capital is at risk if you invest. Occuity Ltd is registered in England and Wales with Company No. 12192959 and Registered Office at 27 Old Gloucester Street, London, United Kingdom WCIN 3AX.